Physician profile
Sohum Trivedi
NPI 1932620291
$3,934.06
in general payments reported to CMS, 2019-2025
31 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $88.82 · 2021: $443 · 2022: $289 · 2023: $624 · 2024: $1,654 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $754.88 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $499.73 | 2020-2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $365.92 | 2022-2025 | Epidiolex |
| Sk Life Science, INC. | $338.45 | 2021-2025 | Xcopri |
| Abbvie INC. | $331.78 | 2023-2025 | Qulipta, Ubrelvy |
| Greenwich Biosciences, INC. | $331.25 | 2019-2021 | |
| Aucta Pharmaceuticals, INC. | $167.54 | 2024-2025 | Motpoly Xr |
| Pfizer INC. | $166.69 | 2019-2025 | |
| Livanova USA, INC. | $152.26 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $122.79 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $115.46 | 2023-2024 | Emgality, Reyvow |
| Neuropace, INC. | $102.12 | 2023 | |
| Otter Pharmaceuticals, LLC | $90.37 | 2025 | Sympazan |
| Alexion Pharmaceuticals, INC. | $61.93 | 2019-2025 | Koselugo |
| Acadia Pharmaceuticals INC | $33.73 | 2024-2025 | Daybue |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $31.74 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $30.34 | 2024 | Nuedexta |
| Nobelpharma America, LLC | $24.27 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.09 | 2020 | |
| Akcea Therapeutics, INC. | $19.75 | 2019 | |
| Zogenix INC. | $19.34 | 2021 | |
| Eisai INC. | $19.32 | 2021 | |
| Genzyme Corporation | $17.38 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $16.39 | 2022 | |
| Novocure INC. | $15.81 | 2023 | Optune |
| Collegium Pharmaceutical, INC. | $14.93 | 2025 | Jornay Pm |
| Aquestive Therapeutics, INC. | $14.64 | 2024 | |
| Biocodex, INC. | $14.08 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.28 | 2024 | Austedo Xr |
| Genentech USA, INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohum Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.